Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: Most Effective Med For Social Phobia: Moclobemide » petter

Posted by SLS on August 30, 2001, at 11:47:57

In reply to Re: Most Effective Med For Social Phobia: Moclobemide, posted by petter on August 30, 2001, at 9:04:14

> Hello, just a note, I've used moclobemide for
> about 5 years now for atypical depression. I only
> use half a 150 mg tab. a day. It doesn't get at
> the core of the depression, but it gets me out of
> bed, prevents the insomniac/hyper episodes I used to
> get in the spring and fall, and keeps me from
> lapsing into a more severe oversleeping depression
> in the winter. I am pleased with what it does
> for these more physical-type symptoms. I get mine
> from Canada. I wish the US would just approve it
> and let doctors and their patients decide what
> it's good for. It's a safe drug that does have
> its uses.
>
 --John

Hi John.

I agree with you. The more tools we have at our disposal, the better. I made the comment along another thread that almost every marketed antidepressant in the world is a miracle drug for at least some people. The nice thing about moclobemide is that it most often brings about significant relief from depression during the first week.

I feel demoralized that several newer medications that I would have liked to have tried have been shelved by their manufacturers.

Brasofensine by NeuroSearch: DA reuptake inhibition – developed for Parkinson’s – lack of comittment by co-sponsors.

Brofaromine (Consonar) by Ciba-Geigy: RIMA, 5-HT reuptake inhibition – developed for depression and social anxiety - withdrawn by the company from European markets for unspecified non-medical reasons.

Befloxatone – Bristol-Myers Squibb: – RIMA – developed for depression and social phobia – “no significant beneficial effect was achieved in phase III.”


* NS2389 by NeuroSearch: – DA + NE + 5-HT reuptake inhibition – developed for depression – decision not to appropriate funds for phase II safety requirements.

Cool. Update:

“COPENHAGEN (AFX) - NeuroSearch AS said it and GlaxoSmithKline PLC are resuming their collaboration on the antidepressant NS2389.

http://www.hemscott.com/scripts/AFXnewstory.dll/text?EPIC=GSK&SerialNumber=1695&NewsType=COM&Indate=16/05/2001


- Scott

 

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:SLS thread:35977
URL: http://www.dr-bob.org/babble/20010828/msgs/76963.html